FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

Source: 
Xconomy
snippet: 

A Vertex Pharmaceuticals partnership with CRISPR Therapeutics to test a genetically engineered drug in patients as a treatment for sickle cell disease has been dealt a setback.